Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2017;10(2):72-75.
doi: 10.1007/s12254-017-0339-z. Epub 2017 Jun 1.

ASH Meeting 2016: developments in hemostaseology

Clemens Feistritzer  1 , Birgit Mosheimer  2
Affiliations
Review

ASH Meeting 2016: developments in hemostaseology

Clemens Feistritzer et al. Memo. 2017.

Abstract

During the annual meeting of the American Society of Hematology (ASH) in San Diego/California, novel developments in the field of hemostaseology were presented. Alternative treatment strategies besides factor replacement were discussed for patients with hemophilia. One of the highlights of the meeting in this year's plenary session was the presentation of successful adeno-associated virus mediated gene transfer in patients with hemophilia B leading to sustained elevation of factor IX:C (FIX:c). Other alternative treatment approaches in patients with hemophilia A may include bispecific antibodies mimicking factor VIIIa (FVIIIa) activity or disrupting anticoagulant proteins. Focusing on anticoagulation, data on the use of direct oral anticoagulants (DOACs) in cancer patients with atrial fibrillation as well as treatment of superficial vein thrombosis with rivaroxaban were presented. In this short review, we try to highlight the most important presentations during the ASH meeting 2016.

Keywords: Anticoagulation; Atrial fibrillation; Cancer; Gene transfer; Hemophilia.

PubMed Disclaimer

Conflict of interest statement

C. Feistritzer and B. Mosheimer declare that they have no competing interests.

References

    1. George LA, Sullivan SK, Giermasz A, et al. Spk-9001: adeno-associated virus mediated gene transfer for hemophilia B achieves sustained mean factor IX activity levels of 〉30 % without Immunosuppression; ASH 2016 plenary session #003. Blood. 2016;128:3. doi: 10.1182/blood-2016-10-742759. - DOI
    1. Shima M, Hanabusa H, Taki M, et al. Factor VIII-mimetic function of humanized Bispecific antibody in hemophilia A. N Engl J Med. 2016;374(21):2044–2053. doi: 10.1056/NEJMoa1511769. - DOI - PubMed
    1. Shah S, Datta YH, Norby F, et al. Direct oral anticoagulants in patients with cancer. ASH 2016 #877. Blood. 2016;128:877. doi: 10.1182/blood-2016-03-705012. - DOI - PMC - PubMed
    1. Beyer-Westendorf J, Schellong SM, Gerlach H, et al. Prevention of thromboembolic complications in patients with superficial-vein thrombosis given rivaroxaban or fondaparinux: the open-label, randomised, non-inferiority SURPRISE phase 3b trial. Lancet Haematol. 2017;4(3):e105–e113. doi: 10.1016/S2352-3026(17)30014-5. - DOI - PubMed
    1. Cosmi B. Management of superficial vein thrombosis. J Thromb Haemost. 2015;13(7):1175–1183. doi: 10.1111/jth.12986. - DOI - PubMed

LinkOut - more resources